跳转至内容
Merck
CN
  • Effects of two novel nucleoside analogues on different hepatitis B virus promoters.

Effects of two novel nucleoside analogues on different hepatitis B virus promoters.

World journal of gastroenterology (2008-03-20)
Xing-Xing He, Ju-Sheng Lin, Ying Chang, Ying-Hui Zhang, Yan Li, Xiao-Yan Wang, Dong Xu, Xiao-Ming Cheng
摘要

To explore the effects of the nucleoside analogues beta-L-D4A and beta-LPA on hepatitis B virus (HBV) promoters. Four HBV promoters were amplified by polymerase chain reaction (PCR) and subcloned into the expression vector pEGFP-1. The four recombinants controlled by HBV promoters were confirmed by restriction analysis and sequencing. Human hepatoma HepG2 cells transfected with the recombinant plasmids were treated with various concentrations of beta-L-D4A and beta-LPA. Then, enhanced green fluorescent protein (EGFP)-positive cells were detected by fluorescence microscopy and using a fluorescence activated cell sorter (FACS). Four HBV promoters were separately obtained and successfully cloned into pEGFP-1. Expression of EGFP under the control of the surface promoter (Sp) and the X promoter (Xp) was inhibited by beta-L-D4A in a dose-dependent manner, while expression of EGFP under the control of the core promoter (Cp) and Xp was inhibited by beta-LPA in a dose-dependent manner. The two novel nucleoside analogues investigated here can inhibit the activities of HBV promoters in a dose-dependent manner. These findings may explain the mechanisms of action by which these two novel compounds inhibit HBV DNA replication.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
2′,3′-脱氧腺苷, ≥97% (HPLC)